Saudi Chemical Company Holding (SCCH) has struck a deal with GlaxoSmithKline to make pharmaceutical products in the Kingdom.
SCCH unit AJA Pharmaceutical Industries will team up with GlaxoSmithKline Consumer Healthcare Saudi in a five-year production deal worth SR100 million (US$27 million), the company said in a Saudi stock exchange filing on Thursday, June 3.
The new partnership would help create more jobs for Saudis in the Kingdom’s pharmaceuticals sector, said SCCH CEO Thamer Al-Muhid. “Our mission is to be the partner of choice,” he said.
Saudi Arabia aims to diversify its economy away from oil by adding more high value jobs at home and replacing imports with domestic manufacturing in key sectors such as pharmaceuticals.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Charter to Acquire Cox Communications in $35 Billion Deal
May 22, 2025 by
CPI
FTC Targets Media Watchdog Over Alleged Collusion Against Musk’s X
May 22, 2025 by
CPI
FTC Drops Antitrust Case Accusing Pepsi of Squeezing Small Retailers
May 22, 2025 by
CPI
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
DOJ Opens Antitrust Probe of Google’s AI Partnership with Character.AI
May 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros